why choose us

First received: November 23, 2022

Clinical Trial: Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Ovarian Cancer

Study Type: INTERVENTIONAL


Official Title: Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer

Brief Summary: To learn if adding lurbinectedin to the combination of paclitaxel and bevacizumab can help to control advanced cancer.

Read more